进行性表型慢性纤维化间质性肺疾病的患病率与预后
42.1%患者符合进行性表型标准(IPF中59.4%,非IPF FILD中26.6%,p<0.01)。进行性表型是无移植生存的独立预测因素(HR 3.36,95%CI 2.68-4.23,p<0.01),非IPF FILD进行性表型患者生存与IPF相似(HR 1.12,95%CI 0.85-1.48,p=0.42)。
要点
- 非IPF纤维化型ILD中约四分之一在24个月内出现进行性表型。
- 进行性表型是无移植生存的独立预测因素(HR 3.36)。
- 非IPF FILD进行性表型患者生存与IPF患者相似。
核心结论
- 超过四分之一的非IPF FILD患者出现进行性表型,而IPF患者约为60%。
- 非IPF FILD进行性表型患者的生存与IPF相似。
研究设计与样本
- 研究连续纳入初诊纤维化型间质性肺疾病(FILD)患者,随访24个月评估进行性纤维化。
主要发现
- 在IPF和非IPF FILD中,进行性表型患者与无进行性表型患者的无移植生存期均存在差异(p<0.01)。
- 多变量分析显示进行性表型是无移植生存的独立预测因素(HR 3.36,95%CI 2.68-4.23,p<0.01)。
- 非IPF FILD进行性表型患者与IPF患者的无移植生存期无差异(HR 1.12,95%CI 0.85-1.48,p=0.42)。
关键数值与推荐
- 进行性表型定义为满足以下至少一项:FVC相对下降≥10%;FVC相对下降≥5%且<10%伴DLCO相对下降≥15%;HRCT纤维化增加或症状进展。
临床怎么用
- 对纤维化型ILD患者应在24个月内监测FVC、DLCO、HRCT及症状以识别进行性表型。
- 非IPF FILD患者出现进行性表型时,其生存预后与IPF相似,提示需积极评估与管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The development of clinically progressive fibrosis complicates a wide array of interstitial lung diseases (ILDs). However, there are limited data regarding its prevalence and prognosis. METHODS: We analysed consecutive patients seen for initial evaluation of a fibrosing form of ILD (FILD). Patients were evaluated for evidence of progressive fibrosis over the first 24 months of follow-up. We defined a progressive phenotype as the presence of at least one of the following: a relative decline in forced vital capacity (FVC) of ≥10%; a relative decline in FVC of ≥5%-<10% with a relative decline in diffusing capacity of the lung for carbon monoxide of ≥15%, increased fibrosis on HRCT or progressive symptoms. RESULTS: Eight hundred and forty-four patients (397 with idiopathic pulmonary fibrosis [IPF] and 447 non-IPF FILD) made up the final analysis cohort. Three hundred and fifty-five patients (42.1%) met the progressive phenotype criteria (59.4% of IPF patients and 26.6% of non-IPF FILD patients, p <0.01). In both IPF and non-IPF FILD, transplantation-free survival differed between patients with a progressive phenotype and those without (p <0.01). Multivariable analysis showed that a progressive phenotype was an independent predictor of transplantation-free survival (hazard ratio [HR]: 3.36, 95% CI: 2.68-4.23, p <0.01). Transplantation-free survival did not differ between non-IPF FILD with a progressive phenotype and IPF (HR: 1.12, 95% CI: 0.85-1.48, p = 0.42). CONCLUSION: Over one-fourth of non-IPF FILD patients develop a progressive phenotype compared to approximately 60% of IPF patients. The survival of non-IPF FILD patients with a progressive phenotype is similar to IPF.
引用
- Takei R, Brown KK, Yamano Y, et al. Prevalence and prognosis of chronic fibrosing interstitial lung diseases with a progressive phenotype. Respirology. 2022. PMID: 35293077. doi:10.1111/resp.14245
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。